•
Dec 31, 2022
Third Harmonic Q4 2022 Earnings Report
Financial results announced for fourth quarter and year-end 2022.
Key Takeaways
Third Harmonic Bio reported its Q4 and year-end 2022 financial results, highlighting progress in preclinical development of a next-generation oral KIT inhibitor for mast cell-mediated inflammatory diseases. The company's cash and cash equivalents totaled $288.9 million as of December 31, 2022.
Progressing preclinical next-generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases.
Observed promising preliminary clinical activity in Phase 1b clinical trial of THB001.
Discontinued Phase 1b clinical trial of THB001 in chronic inducible urticaria following observation of asymptomatic liver transaminitis in two subjects.
Making meaningful progress toward selecting a next-generation KIT inhibitor development candidate in 2023.